PL2983784T3 - Kompozycja zawierająca białko HIP/PAP lub jego pochodną do leczenia insulinooporności - Google Patents

Kompozycja zawierająca białko HIP/PAP lub jego pochodną do leczenia insulinooporności

Info

Publication number
PL2983784T3
PL2983784T3 PL14720662T PL14720662T PL2983784T3 PL 2983784 T3 PL2983784 T3 PL 2983784T3 PL 14720662 T PL14720662 T PL 14720662T PL 14720662 T PL14720662 T PL 14720662T PL 2983784 T3 PL2983784 T3 PL 2983784T3
Authority
PL
Poland
Prior art keywords
hip
derivatives
insulin resistance
composition including
treating insulin
Prior art date
Application number
PL14720662T
Other languages
English (en)
Inventor
Fabrizio ANDREELLI
Paul Amouyal
Christophe MAGNAN
Céline CRUCIANI-GUGLIELMACCI
Jamila Faivre
Marion Darnaud
Laure Jamot
Christian Brechot
Gilles Amouyal
Original Assignee
The Healthy Aging Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Healthy Aging Company filed Critical The Healthy Aging Company
Publication of PL2983784T3 publication Critical patent/PL2983784T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL14720662T 2013-04-10 2014-04-04 Kompozycja zawierająca białko HIP/PAP lub jego pochodną do leczenia insulinooporności PL2983784T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1353245A FR3004354A1 (fr) 2013-04-10 2013-04-10 Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
PCT/FR2014/050821 WO2014167230A1 (fr) 2013-04-10 2014-04-04 Composition comprenant la protéine hip/pap ou l'un de ses dérivés pour le traitement de la résistance à l'insuline
EP14720662.7A EP2983784B1 (fr) 2013-04-10 2014-04-04 Composition comprenant la protéine hip/pap ou l'un de ses dérivés pour le traitement de la résistance à l'insuline

Publications (1)

Publication Number Publication Date
PL2983784T3 true PL2983784T3 (pl) 2020-06-15

Family

ID=49151035

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14720662T PL2983784T3 (pl) 2013-04-10 2014-04-04 Kompozycja zawierająca białko HIP/PAP lub jego pochodną do leczenia insulinooporności

Country Status (9)

Country Link
US (1) US9629896B2 (pl)
EP (1) EP2983784B1 (pl)
JP (2) JP6890970B2 (pl)
CN (1) CN105658280B (pl)
DK (1) DK2983784T3 (pl)
ES (1) ES2755177T3 (pl)
FR (1) FR3004354A1 (pl)
PL (1) PL2983784T3 (pl)
WO (1) WO2014167230A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
CN117986343A (zh) * 2017-07-13 2024-05-07 健康老龄化公司 用于保护氧敏感革兰氏阳性菌的REG3α
CN107936111B (zh) * 2017-12-16 2021-09-07 广州安辰新药研究院有限公司 一种hip/pap蛋白的制备方法
EP4252766A1 (en) * 2022-04-01 2023-10-04 The Healthy Aging Company Hip/pap protein or a derivative thereof for treating and/or preventing a disorder characterized by a high cxcl5 serum level in an individual

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094958A1 (en) * 2002-05-09 2003-11-20 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
EP1488798A1 (en) 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
US8211430B2 (en) * 2005-03-04 2012-07-03 Curedm Group Holdings, Llc Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
WO2006118085A1 (ja) * 2005-04-26 2006-11-09 Stelic Institute Of Regenerative Medicine 肝細胞複製促進剤およびインスリン抵抗性改善剤
US7393919B2 (en) 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
JP5864077B2 (ja) * 2006-09-08 2016-02-17 ロード アイランド ホスピタル アルコール誘発性肝疾患の治療、予防および回復
EP2260857A1 (en) * 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
US20140235552A1 (en) * 2013-02-15 2014-08-21 Claresa Levetan Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline

Also Published As

Publication number Publication date
JP2020007365A (ja) 2020-01-16
JP6890970B2 (ja) 2021-06-18
CN105658280A (zh) 2016-06-08
FR3004354A1 (fr) 2014-10-17
US20160058833A1 (en) 2016-03-03
EP2983784A1 (fr) 2016-02-17
JP2016518354A (ja) 2016-06-23
DK2983784T3 (da) 2019-11-25
WO2014167230A1 (fr) 2014-10-16
US9629896B2 (en) 2017-04-25
CN105658280B (zh) 2020-05-15
ES2755177T3 (es) 2020-04-21
EP2983784B1 (fr) 2019-09-11

Similar Documents

Publication Publication Date Title
IL264541B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
HRP20181863T1 (hr) Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HK1217330A1 (zh) -苯基-氨甲酰衍生物及其作爲藥物用於治療乙型肝炎的用途
HK1215567A1 (zh) 五元併六元雜環化合物、其製備方法、藥物組合物和應用
IL246757A0 (en) New insulin histories and their medical uses
SI2945642T1 (sl) Protein faktorja 1 za uporabo pri zdravljenju ali preprečevanju bolezni
IL257173A (en) New insulin histories and their medical uses
EP3012256A4 (en) HETEROCYCLIC BENZIMIDAZOLE-2-PIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARATION AND USE THEREOF
PL2983784T3 (pl) Kompozycja zawierająca białko HIP/PAP lub jego pochodną do leczenia insulinooporności
EP3013333A4 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB201610823D0 (en) Heterocyclic compounds and medical uses
AP2015008814A0 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b